CapsoVision, Inc. ( (CV)) has shared an announcement. On December 29, 2025, CapsoVision, Inc. announced it had submitted a 510(k) application to the U.S. Food and Drug Administration for an ...

SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions ...

Weil's new Ask DealVision program uses AI to deliver rapid responses to PE M&A questions. The system leverages internal firm data going back to 2018 to cut time off of common PE M&A tasks. The product ...

One of the drawbacks to most AI implementations is that much of the processing is performed in the cloud, which usually means uploading your personal information to servers you have no control over.

Does Saturn’s moon Titan have a subsurface global ocean where life as we know it could exist? This is what a recent study published in Nature hopes to address as an international team of researchers ...

Many workers fear artificial intelligence is coming for their jobs, an idea bolstered by warnings from AI leaders and anecdotes from a recent Federal Reserve report. Yet new research finds the ...

Four ways to think about this year's reckoning. Some disillusionment was inevitable. When OpenAI released a free web app called ChatGPT in late 2022, it changed the course of an entire industry—and ...

Everyone in tech agrees we’re in a bubble. They just can’t agree on what it looks like — or what happens when it pops. MIT Technology Review Explains: Let our writers untangle the complex, messy world ...

BigBear.ai has struggled since its public debut four years ago. It may struggle to grow organically over the next few years. Innodata offers better growth at a much cheaper valuation. Before ...

WEST LAFAYETTE, Ind. — Purdue University on Friday (Dec. 12) unveiled a broad strategy of AI@Purdue across five functional areas: Learning with AI, Learning about AI, Research AI, Using AI and ...

BigBear.ai’s stock remains far below its debut price. It faces tough macro and competitive headwinds. Its stock doesn’t look cheap relative to its growth potential. Like many other SPAC-backed ...